FDA accepts Avycaz sNDA to include the treatment of complicated urinary tract infections and complicated intra-abdominal infections in pediatric patients . Allergan.

Allergan plc announced that the FDA has accepted for review the company's supplemental New Drug Application (sNDA) for AvyCaz(ceftazidime and avibactam), seeking to expand the label to include the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI), in combination with metronidazole, in pediatric patients 3 months to less than 18 years of age.

The pediatric sNDA is based on two-active control clinical studies evaluating Avycaz in pediatric patients with cIAI or cUTI, as well as a single-dose pharmacokinetic study. In the cIAI study, the safety and efficacy of Avycaz (in combination with metronidazole) was compared with meropenem. In the cUTI study, Avycaz was compared with cefepime. Overall, the findings from the pediatric studies were similar to the previous determination of safety for Avycaz for the treatment of adult patients with cIAI or cUTI, and no new safety concerns were identified in pediatric patients. In addition, descriptive efficacy in the pediatric studies was consistent with data from studies in adults with cIAI and cUTI, and favorable clinical and microbiological responses were both observed against the predominant cIAI and cUTI pathogens.